Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q8NDW8

UPID:
TT21A_HUMAN

ALTERNATIVE NAMES:
Stress-inducible protein 2

ALTERNATIVE UPACC:
Q8NDW8; A1L388; B4DYF6; B4DYJ3; D3YTE7; D4PHA5; Q6P5W8; Q8N7G5; Q8NA02

BACKGROUND:
The protein Tetratricopeptide repeat protein 21A, alternatively known as Stress-inducible protein 2, is integral to the development of sperm, ensuring proper flagellar assembly and intraflagellar transport. This process is vital for the motility and morphology of spermatozoa.

THERAPEUTIC SIGNIFICANCE:
Linked to Spermatogenic failure 37, characterized by severe morphological abnormalities in sperm, the protein's gene mutations underscore its importance. Exploring Tetratricopeptide repeat protein 21A's function offers promising avenues for infertility treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.